Comparison of conventional radiography with full body magnetic resonance and analysis of bone metabolism analysis in patients with multiple myeloma
Authors:
P. Puščiznová 1; P. Petrová 2; J. Hrbek 3; M. Heřman 3; T. Pika 1; J. Bačovský 1; J. Minařík 1
Authors place of work:
Hemato-onkologická klinika LF UP a FN Olomouc
1; Oddělení klinické biochemie FN a LF UP Olomouc
2; Radiologická klinika
3
Published in the journal:
Klin. Biochem. Metab., 23 (44), 2015, No. 2, p. 48-52
Summary
Objective:
Comparison of radiodiagnostic methods, conventional radiography (X-ray) and whole-body magnetic resonance (MR-WB), to myeloma bone disease (MBD) and to the levels of selected markers of bone metabolism and bone marrow microenvironment.
Material and Methods:
We examined 32 patients with multiple myeloma at the time of diagnosis. All patients were examined by X-ray and whole-body magnetic resonance. Following parameters of bone marrow microenvironment were assessed: osteocalcin (OC), bone alkaline phosphatase (bALP), parathormone (PTH), carboxy-terminal telopeptide of type-I collagen (ICTP),N -terminal propeptide of procollagen type-I (PINP), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), syndecan-1 / CD138 (SYN), vascular endothelial growth factor (VEGF), osteoprotegerin (OPG), osteopontin (OPN), endostatin (ES), macrophage inflammatory protein 1α and 1β (MIP-1α, MIP-1β), interleukin-17 (IL-17), and angiogenin (ANG).
Results:
Magnetic resonance imaging was more useful than radiography for 40.63 % of patients, these two methods were exactly the same in 34 % and in 25.37 % they were very similar. There is a positive correlation between X-ray and ICTP (kk=0.306, p=0.023), PINP (kk=0.274, p=0.039) and OPN (kk=0.331, p=0.013). For other parameters the correlation was not statistically significant.
Conclusion:
X-ray has lower sensitivity in assessing of MBD. Our results recommend imaging with WB-MR. Indicators of bone marrow microenvironment have a potential to improve the understanding of biological processes in MBD. Larger group of patients should be evaluated to assess their real benefits. Three parameters are promising in the assessment of the MBD´s extent - ICTP, PINP and OPN.
Keywords:
multiple myeloma, myeloma bone disease, conventional radiography, magnetic resonance, bone marrow microenvironment.
Zdroje
1. Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 2014, 15,12, p. 538-548.
2. Dimopoulos, M., Terpos, E., Comenzo, R. L., et al. International Myeloma Working Group consensus statement and guidelines regarding the current role of ima-ging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia, 2009, 23, p. 1545-1556.
3. Vaníček, J., Krupa, P., Adam, Z. Přínos jednotlivých zobrazovacích metod pro diagnostiku a sledování akti-vity mnohočetného myelomu. Vnitřní Lékařství, 2010, 56, p. 585–590.
4. Roodman, G. D. Pathogenesis of myeloma bone dise-ase. Leukemia, 2009, 23, p. 435-441.
5. Mundy, G. R, Raisz, L. G., Cooper, R. A., et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. New England Journal of Medicine, 1974, 291, p. 1041-1046.
6. Durie, B. G., Salmon, S. E. A clinical staging system for multiple myeloma, Correlation of Measured Myeloma Cell Mass with Presenting. Cancer, 1975, 36, p. 842-854.
7. Durie, B. G. The role of anatomic and functional sta-ging in myeloma: description of Durie/Salmon plus sta-ging system. European Journal of Cancer, 2006, 42, p. 1539-1543.
8. Sezer, O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist, 2009, 14, p. 276-283.
9. Healy, C. F., Murray, J. G., Eustace, S. J., et al. Multiple Myeloma: A Review of Imaging Features and Radiological Techniques, Bone marrow research, 2011, 2011, p. 1-9.
10. Minařík, J., Hrbek, J., Pika, T., et al. Srovnání přínosu konvenčního RTG, celotělové magnetické rezonance a celotělového nízkodávkového CT v diagnostice myelomové kostní nemoci. Osteologický bulletin, 2013, 18, p. 143-147.
11. Terpos, E., Moulopoulos, L. A., Dimopoulos, M. A. Advances in imaging and the management of myeloma bone disease. Journal of Clinical Oncology, 2011, 29, p. 1907-1915.
12. D’Sa, S., Abildgaard, N., Tighe, J., et al. Guidelines for the use of imaging in the management of myeloma. British Journal of Haematology, 2007, 137, p. 49-63.
13. Regelink, J. C., Minnema, M. C., Terpos, E., et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. British Journal of Haematology, 2013, 162, p. 50-61.
14. Mechl, M., Neubauer, J., Krejčiřík, P., et al. Celotělové vyšetření pomocí magnetické rezonance se zobrazením difuze u nemocných s mnohočetným myelomem–první zkušenosti. Čes. Radiol., 2007, 61, p. 364-369.
15. Jakob, C., Zavrski, I., Heider, U., et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are ele-vated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lac-king lytic bone lesions in conventional radiography. Clinical Cancer Research, 2003, 9, p. 3047-3051.
16. Ščudla, V., Budíková, M., Petrová, P., et al. Analýza sérových hladin vybraných biologických ukazatelů u monoklonální gamapatie nejistého významu a mnohočetného myelomu. Klinická Onkologie, 2010, 23, p. 171-181.
17. Sezer, O., Jakob, C., Eucker, J., et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. European Journal of Haematology, 2001, 66, p. 83-88.
18. Choi, S. J., Cruz, J. C., Craig, F., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood, 2000, 96, p. 671-675.
19. Sezer, O., Heider, U., Zavrski, I., et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood, 2003, 101, p. 2094-2098.
20. Standal, T., Hjorth-Hansen, H., Rasmussen, T., et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica, 2004, 89, p. 174-182.
21. Jakob, C., Zavrski, I., Heider, U., et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are ele-vated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lac-king lytic bone lesions in conventional radiography. Clinical Cancer Research, 2003, 9, p. 3047-3051.
22. Haylock, D. N., Nilsson, S. K. Osteopontin: a bridge between bone and blood. British Journal of Haemato-logy, 2006, 134, p. 467-474.
23. Robbiani, D. F., Colon, K., Ely, S., et al. Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematological Oncology, 2007, 25, p. 16-20.
24. Colla, S., Morandi, F., Lazzaretti, M., et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia, 2005, 19, p. 2166-2176.
25. Fonseca, R., Trendle, M. C., Leong, T. et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. British Journal of Haematology, 2000, 109, p. 24-29.
26. Abildgaard, N., Brixen, K., Eriksen, E. F., et al. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica, 2004, 89, p. 567-577.
27. Minarik, J., Petrova, P., Bacovsky, J., et al. Serum levels of Dickkopf-1 predict progression free survival in multiple myeloma patiens treated with autologous stem cell transplant but its prognostic value is overcome by the use of novel drugs. Heamatologica, 2014, p. 353-353.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2015 Číslo 2
Najčítanejšie v tomto čísle
- The attitude to determination of hemoglobin in stools in quantitative analysis
- Recommendation of the Czech Society of Clinical Biochemistry: the use of cardiac troponins in suspected acute coronary syndrome
- New recommendation of professional Czech Society of Clinical Biochemistry and Czech Society of Cardiology
- Comparison of conventional radiography with full body magnetic resonance and analysis of bone metabolism analysis in patients with multiple myeloma